Stock Screener
US stocks rated by the Lician Quant model: a 1–5 rating and A+ to F grades for valuation, growth, profitability, momentum and EPS revisions, each against the stock’s sector. Filter, sort by any factor and share the URL.
88 stocks · Strong Buy or Buy · Healthcare · Profitability ≥ A-
| Stock | Quant ratingRating | ValuationVal | GrowthGrow | ProfitabilityProf | MomentumMom | EPS revisionsRev | Market capMkt cap | P/EP/E | Revenue growthRev YoY | Div. yieldYield | Short % floatShort | Next earningsEarnings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1QTTBQ32 Bio Inc | 5.00Strong Buy | A+ | — | A+ | B | A | $206M | 6.1 | — | — | 57.9% | Nov 12 |
| 2CDNACareDx Inc | 4.98Strong Buy | C+ | B+ | A+ | A+ | A+ | $3.6B | 32.2 | +34.4% | — | 13.6% | — |
| 3HALOHalozyme Therapeutics Inc | 4.97Strong Buy | C | B+ | A+ | A+ | A+ | $14.7B | 35.4 | +41.2% | — | 11.2% | Nov 5 |
| 4OSCROscar Health Inc | 4.97Strong Buy | — | A | A- | A | B- | — | — | +42.8% | — | — | Nov 5 |
| 5REGNRegeneron Pharmaceuticals Inc | 4.95Strong Buy | B+ | C+ | A+ | A | A | $103B | 21.5 | +18.6% | — | 2.1% | — |
| 6PACSPACS Group, Inc. | 4.94Strong Buy | B+ | A | A- | A | B | $7.6B | 28.1 | +16.6% | — | — | — |
| 7CONConcentra Group Holdings Parent, Inc. | 4.94Strong Buy | A- | B- | A- | A+ | B | $5.0B | 25.4 | +14.0% | 0.99% | 3.1% | Nov 5 |
| 8ARQTArcutis Biotherapeutics Inc | 4.92Strong Buy | C+ | A+ | A- | A- | B+ | $3.9B | 137.4 | +76.1% | — | 23.9% | Nov 4 |
| 9GMEDGlobus Medical | 4.91Strong Buy | A+ | A- | A | C | A- | $8.6B | 16.1 | +19.7% | — | 7.3% | Nov 5 |
| 10HRMYHarmony Biosciences Holdings | 4.91Strong Buy | A+ | B | A | C+ | A- | $2.2B | 12.3 | +24.3% | — | — | Nov 4 |
| 11NUTXNutex Health Inc | 4.90Strong Buy | A+ | A- | A | B- | B- | $1.4B | 7.3 | +6.9% | — | — | Nov 5 |
| 12KNSAKiniksa Pharmaceuticals Ltd | 4.89Strong Buy | B- | A+ | A | A+ | C | $4.1B | 37.7 | +58.2% | — | 9.6% | — |
| 13INVAInnoviva Inc | 4.89Strong Buy | A+ | B+ | A+ | C- | A- | $1.5B | 4.3 | +18.8% | — | 10.5% | Nov 4 |
| 14PTGXProtagonist Therapeutics Inc | 4.88Strong Buy | C | A- | A+ | B+ | A | $9.4B | 113.0 | +34.8% | — | — | Nov 5 |
| 15NBIXNeurocrine Biosciences Inc | 4.87Strong Buy | B+ | A | A+ | B- | B | $14.7B | 21.0 | +38.0% | — | 6.6% | — |
| 16VEEVVeeva Systems Inc Class A | 4.85Strong Buy | C+ | B | A+ | A | B+ | $50.6B | 49.9 | +16.5% | — | — | Nov 19 |
| 17MGTXMeiraGTx Holdings PLC | 4.82Strong Buy | A | A+ | A+ | D | B- | $897M | 11.4 | +948.3% | — | 17.6% | Nov 12 |
| 18RIGLRigel Pharmaceuticals Inc | 4.82Strong Buy | A+ | B+ | A+ | A | D- | $895M | 2.8 | +3.3% | — | 18.3% | Nov 5 |
| 19ETONEton Pharmaceuticals Inc | 4.80Strong Buy | D+ | A+ | A- | A- | A- | $1.4B | 113.6 | +81.5% | — | 9.3% | Nov 5 |
| 20EHCEncompass Health Corp | 4.79Strong Buy | B+ | B+ | A | B+ | C+ | $12.7B | 20.4 | +9.5% | 0.72% | 3.4% | — |
| 21MEDPMedpace Holdings Inc | 4.78Strong Buy | B- | B+ | A+ | A- | B- | $17.3B | 35.2 | +24.7% | — | 7.2% | — |
| 22SNYSanofi | 4.77Strong Buy | — | A- | A | C+ | — | — | — | — | — | — | — |
| 23AMGNAmgen Inc | 4.76Strong Buy | B | B- | A+ | A | C+ | $250B | 28.6 | +9.1% | 2.80% | 2.5% | — |
| 24ACADACADIA Pharmaceuticals Inc | 4.75Strong Buy | A | A- | A+ | D | B+ | $3.3B | 8.7 | +11.8% | — | 7.9% | Nov 4 |
| 25VRTXVertex Pharmaceuticals Inc | 4.74Strong Buy | B- | C+ | A+ | B | A | $135B | 30.7 | +10.2% | — | 1.7% | — |
Showing 25 of 88
Source: Lician Quant Grades (SEC EDGAR statements, EODHD prices and estimates); short interest: FINRA; earnings dates: earnings calendar; dividend yield: EODHD fundamentals · Quant run Nov 4, 2026
Grades rank each stock against its sector peers; they are not investment advice. How the rating and grades work · Short interest · Earnings calendar